Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.60 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 8/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.53 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.53 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.53 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.53 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.53 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | ALPG | P10696 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.48 |
| ▸ | HTR6 | P50406 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL762553 | 0.87 | SMN1; SMN2 (0.60) | SMN1; SMN2MAPTLMNAAKR1B10AKR1B1 | |
| SCHEMBL111539 | 0.84 | KAT2B (0.59) | SMN1; SMN2MAPTLMNAAKR1B10AKR1B1 | |
| SCHEMBL4309629 | 0.84 | MAPT (0.62) | SMN1; SMN2MAPTLMNAAKR1B10AKR1B1 | |
| SCHEMBL10576590 | 0.84 | LMNA (0.68) | SMN1; SMN2MAPTLMNAAKR1B10AKR1B1 | |
| SCHEMBL10580319 | 0.84 | MAPT (0.58) | SMN1; SMN2MAPTLMNAAKR1B10AKR1B1 | |
| SCHEMBL29392855 | 0.84 | KAT2B (0.59) | SMN1; SMN2MAPTLMNAAKR1B10AKR1B1 | |
| SCHEMBL29624957 | 0.82 | MAPT (0.50) | SMN1; SMN2DCTPP1MAPTLMNAMAPK1 | |
| SCHEMBL20209060 | 0.82 | MAPT (0.50) | SMN1; SMN2DCTPP1MAPTLMNAMAPK1 | |
| SCHEMBL6400130 | 0.82 | MAPT (0.50) | SMN1; SMN2DCTPP1MAPTLMNAAKR1B10 | |
| Hydrochloric Acid SCHEMBL141377 | 0.82 | KAT2B (0.61) | SMN1; SMN2MAPTLMNAAKR1B10AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9981954-B2 | 2-(pyrazin-2-ylcarbonylaminomethyl) benzimidazolium compounds as epithelial sodium channel inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-05-29 | — | — | US | disclosed |
| US-20180002314-A1 | 2-(PYRAZIN-2-YLCARBONYLAMINOMETHYL) BENZIMIDAZOLIUM COMPOUNDS AS EPITHELIAL SODIUM CHANNEL INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-01-04 | — | — | US | disclosed |
| EP-3022197-B1 | NOVEL TETRA- AND PENTASUBSTITUTED BENZIMIDAZOLIUM COMPOUNDS | BOEHRINGER INGELHEIM INT (DE) | 2017-09-06 | — | — | EP | disclosed |
| WO-2017109182-A1 | COMPOSITION COMPRISING AT LEAST TWO DIFFERENT STARCHES AND A COLOURING AGENT | L'OREAL (FR) | 2017-06-29 | — | — | WO | disclosed |
| US-9439844-B2 | Tri-aromatic azomethine direct dyes comprising at least one unit derived from resorcinol, dyeing composition, method and use | L'OREAL (FR) | 2016-09-13 | — | — | US | disclosed |
| US-9328131-B2 | Benzimidazolium compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-05-03 | — | — | US | disclosed |
| US-9233057-B2 | Particular quinone direct dyes, dye composition comprising at least one such dye, implementation process therefor and use thereof | L'OREAL (FR) | 2016-01-12 | — | — | US | disclosed |
| US-9126985-B2 | Tetra- and pentasubstituted benzimidazolium compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-09-08 | — | — | US | disclosed |
| US-9073954-B2 | 5-substituted benzimidazolium compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-07-07 | — | — | US | disclosed |
| WO-2015063125-A1 | EXPANDED DYEING COMPOSITION COMPRISING AN INERT GAS, A NON-VOLATILE ALKALINE AGENT AND A DYE | L'OREAL (FR) | 2015-05-07 | — | — | WO | disclosed |
| US-20140360523-A1 | PARTICULAR QUINONE DIRECT DYES, DYE COMPOSITION COMPRISING AT LEAST ONE SUCH DYE, IMPLEMENTATION PROCESS THEREFOR AND USE THEREOF | L'OREAL (FR) | 2014-12-11 | — | — | US | disclosed |
| EP-2791106-A1 | PARTICULAR QUINONE DIRECT DYES, DYE COMPOSITION COMPRISING AT LEAST ONE SUCH DYE, IMPLEMENTATION PROCESS THEREFOR AND USE THEREOF | L'OREAL (FR) | 2014-10-22 | — | — | EP | disclosed |
| WO-2014131872-A2 | COSMETIC COMPOSITION IN THE FORM OF AN OIL-IN-WATER NANOEMULSION FOR THE DIRECT DYEING OF KERATIN FIBRES | L'OREAL (FR) | 2014-09-04 | — | — | WO | disclosed |
| WO-2014102324-A1 | DYEING METHOD EMPLOYING A DYE AND A CHAOTROPIC SALT | L'OREAL (FR) | 2014-07-03 | — | — | WO | disclosed |
| WO-2013087770-A1 | PARTICULAR QUINONE DIRECT DYES, DYE COMPOSITION COMPRISING AT LEAST ONE SUCH DYE, IMPLEMENTATION PROCESS THEREFOR AND USE THEREOF | L'OREAL (FR) | 2013-06-20 | — | — | WO | disclosed |
| WO-2011079087-A1 | ENAC BLOCKERS | GLAXO GROUP LIMITED (GB) | 2011-06-30 | — | — | WO | disclosed |
| WO-2011079087-A1 | ENAC BLOCKERS | GLAXO GROUP LIMITED (GB) | 2011-06-30 | — | — | WO | disclosed |
| US-20050153978-A1 | Medicaments | GLAXO GROUP LIMITED (GB) | 2005-07-14 | — | — | US | disclosed |
| EP-1487441-A2 | BENZIMIDAZOLES AND THEIR USE AS MITOGEN-ACTIVATED- AND RHO-KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-12-22 | — | — | EP | disclosed |
| WO-2003080125-A2 | BENZIMIDAZOLES AND THEIR USE AS MITOGEN-ACTIVATED- AND RHO-KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2003-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180002314-A1 | 2-(PYRAZIN-2-YLCARBONYLAMINOMETHYL) BENZIMIDAZOLIUM COMPOUNDS AS EPITHELIAL SODIUM CHANNEL INHIBITORS | SCNN1A, TRPV1, SCNN1B | SMN1; SMN2 2748/4885DCTPP1 3439/4885MAPT 708/4885 |
| US-20050153978-A1 | Medicaments | GRK1, ROCK1, GRK7 | SMN1; SMN2 1495/4885DCTPP1 3237/4885MAPT 3107/4885 |
| US-20140360523-A1 | PARTICULAR QUINONE DIRECT DYES, DYE COMPOSITION COMPRISING AT LEAST ONE SUCH DYE, IMPLEMENTATION PROCESS THEREFOR AND USE THEREOF | KRT18, SQOR, NDUFB7 | SMN1; SMN2 4815/4885DCTPP1 1653/4885MAPT 255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.